$9.23
+0.46 (+5.25%)
Open$9.21
Previous Close$8.77
Day High$9.45
Day Low$8.77
52W High$23.57
52W Low$1.79
Volume—
Avg Volume781.0K
Market Cap261.67M
P/E Ratio8.77
EPS$2.29
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+202.7% upside
Current
$9.23
$9.23
Target
$27.94
$27.94
$24.18
$27.94 avg
$39.76
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 130.20M | 8.10M | 7.51M |
| Net Income | 72.25M | -2,253,266 | -2,377,750 |
| Profit Margin | 55.5% | -27.8% | -31.6% |
| EBITDA | 38.02M | -3,375,106 | -3,186,219 |
| Free Cash Flow | — | -1,035,116 | -1,228,536 |
| Rev Growth | +155.8% | +18.0% | -0.1% |
| Debt/Equity | 2.29 | 0.78 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |